Stocks
COMPASS Pathways plcCMPS
NASDAQHealthcareBiotechnology$6.39-3.62%
Focused on developing innovative psilocybin therapy for treatment-resistant depression, this biopharmaceutical company has attracted investor attention for its pioneering work in mental health therapeutics. Its lead candidate, COMP360, is in late-stage clinical trials and represents a potential breakthrough in a market with high unmet need.
Market Cap: $613.5M52W Range: $2.25 – $8.90
Congressional Interest in COMPASS Pathways plc (CMPS)
1 member of Congress has disclosed 1 trade in COMPASS Pathways plc (CMPS), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading CMPS?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-01-23 | Shri Thanedar | sell | $1K – $15K |